tradingkey.logo

STAAR Surgical Co

STAA

27.160USD

0.000
Close 09/18, 16:00ETQuotes delayed by 15 min
1.34BMarket Cap
LossP/E TTM

STAAR Surgical Co

27.160

0.000

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated2025-09-17

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
117 / 207
Overall Ranking
295 / 4723
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 9 analysts
Hold
Current Rating
24.625
Target Price
-9.57%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. These lenses provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. The Company is a manufacturer of lenses used worldwide in corrective or refractive surgery. It sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux, and Italy. The Company markets and sells ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. The Company’s EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company also markets and sells an ICL lens to treat hyperopia (farsightedness), which is called Visian ICL.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD 20.21M.%!(EXTRA int=2)
Undervalued
The company’s latest PE is -14.07, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 53.99M shares, decreasing 9.46% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 4.38M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.61.

Financial Health

Currency: USD Updated2025-09-17

The company's current financial score is 6.29, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 44.32M, representing a year-over-year decrease of 55.23%, while its net profit experienced a year-over-year decrease of 327.84%.

Score

Industry at a Glance

Previous score
6.29
Change
0

Financials

9.50

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data

Quality of Earnings

6.74

Operational Efficiency

4.14

Growth Potential

4.01

Shareholder Returns

7.08

Company Valuation

Currency: USD Updated2025-09-17

The company’s current valuation score is 1.20, which is lower than the Healthcare Equipment & Supplies industry's average of 2.00. Its current P/E ratio is -14.07, which is -734.98% below the recent high of 89.33 and 556.96% above the recent low of 64.29.

Score

Industry at a Glance

Previous score
2.00
Change
-0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 117/207
No Data

Earnings Forecast

Currency: USD Updated2025-09-17

The company’s current earnings forecast score is 6.20, which is lower than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for STAAR Surgical Co is 28.00, with a high of 28.00 and a low of 16.00.

Score

Industry at a Glance

Previous score
6.20
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts
Hold
Current Rating
24.625
Target Price
-9.33%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

118
Total
7
Median
8
Average
Company name
Ratings
Analysts
STAAR Surgical Co
STAA
9
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
29
1
2
3
...
24

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated2025-09-17

The company’s current price momentum score is 4.51, which is lower than the Healthcare Equipment & Supplies industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 28.03 and the support level at 26.64, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
4.32
Change
0.19

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.697
Neutral
RSI(14)
56.683
Neutral
STOCH(KDJ)(9,3,3)
18.057
Sell
ATR(14)
0.470
High Vlolatility
CCI(14)
-134.423
Sell
Williams %R
87.097
Oversold
TRIX(12,20)
0.368
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(3)
Neutral(0)
Buy(3)
Indicators
Value
Direction
MA5
27.384
Sell
MA10
27.597
Sell
MA20
27.583
Sell
MA50
24.164
Buy
MA100
21.024
Buy
MA200
20.828
Buy

Institutional Confidence

Currency: USD Updated2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 109.59%, representing a quarter-over-quarter increase of 1.02%. The largest institutional shareholder is The Vanguard, holding a total of 4.38M shares, representing 8.88% of shares outstanding, with 25.17% decrease in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Broadwood Capital, Inc.
13.55M
+8.75%
BlackRock Institutional Trust Company, N.A.
7.01M
-4.17%
The Vanguard Group, Inc.
Star Investors
5.41M
-7.52%
Soleus Capital Management, L.P.
2.56M
--
Armistice Capital LLC
3.00M
+244.04%
Resona Asset Management Co., Ltd.
2.17M
+44.62%
Yunqi Capital Limited
1.94M
+152.48%
State Street Global Advisors (US)
1.99M
-2.82%
Geode Capital Management, L.L.C.
1.19M
+1.26%
BofA Global Research (US)
953.61K
+152.92%
1
2

Risk Assessment

Currency: USD Updated2025-09-17

The company’s current risk assessment score is 3.17, which is lower than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 0.84. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
3.17
Change
0
Beta vs S&P 500 index
0.84
VaR
+5.48%
240-Day Maximum Drawdown
+57.94%
240-Day Volatility
+81.42%
Return
Best Daily Return
60 days
+46.13%
120 days
+46.13%
5 years
+46.13%
Worst Daily Return
60 days
-7.00%
120 days
-8.51%
5 years
-24.68%
Sharpe Ratio
60 days
+2.53
120 days
+1.48
5 years
-0.03
Risk Assessment
Maximum Drawdown
240 days
+57.94%
3 years
+80.98%
5 years
+90.72%
Return-to-Drawdown Ratio
240 days
-0.42
3 years
-0.26
5 years
-0.14
Skewness
240 days
+3.78
3 years
+1.90
5 years
+1.33
Volatility
Realised Volatility
240 days
+81.42%
5 years
+65.30%
Standardised True Range
240 days
+4.07%
5 years
+12.27%
Downside Risk-Adjusted Return
120 days
+351.20%
240 days
+351.20%
Maximum Daily Upside Volatility
60 days
+98.82%
Maximum Daily Downside Volatility
60 days
+96.19%
Liquidity
Average Turnover Rate
60 days
+3.24%
120 days
+2.56%
5 years
--
Turnover Deviation
20 days
+261.25%
60 days
+77.73%
120 days
+40.56%

Peer Comparison

Healthcare Equipment & Supplies
STAAR Surgical Co
STAAR Surgical Co
STAA
5.21 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
7.91 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
Insulet Corp
PODD
7.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stevanato Group SpA
Stevanato Group SpA
STVN
7.84 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Abbott Laboratories
Abbott Laboratories
ABT
7.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Transmedics Group Inc
Transmedics Group Inc
TMDX
7.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI